67 related articles for article (PubMed ID: 8457238)
41. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats.
Choi JS; Jo BW
Int J Pharm; 2004 Aug; 280(1-2):221-7. PubMed ID: 15265561
[TBL] [Abstract][Full Text] [Related]
42. [Phase I study of a tolmetin-paracetamol (AU-8001) ester].
Cuena R; Rubio A; Azanza JR; Honorato J
Rev Med Univ Navarra; 1987; 31(3):131-4. PubMed ID: 3333890
[TBL] [Abstract][Full Text] [Related]
43. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin.
Roy SD; Manoukian E
J Pharm Sci; 1994 Nov; 83(11):1548-53. PubMed ID: 7891272
[TBL] [Abstract][Full Text] [Related]
44. Influence of sex on the pharmacokinetics of tolmetin in the rat.
Jiménez M; Pérez-Urizar J; Flores-Murrieta FJ
J Pharmacol Toxicol Methods; 1999 Oct; 42(2):103-5. PubMed ID: 10924894
[TBL] [Abstract][Full Text] [Related]
45. [Pharmacokinetic and biopharmaceutic study of chloracetadol administered by the intravenous and rectal routes in rabbits].
Montserrat M; Obach R; Martin A; Domenech J
Ann Pharm Fr; 1982; 40(4):365-72. PubMed ID: 6984305
[No Abstract] [Full Text] [Related]
46. Disposition and irreversible plasma protein binding of tolmetin in humans.
Hyneck ML; Smith PC; Munafo A; McDonagh AF; Benet LZ
Clin Pharmacol Ther; 1988 Jul; 44(1):107-14. PubMed ID: 3390998
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of indomethacin octyl ester (prodrug) and indomethacin produced from the prodrug.
Ogiso T; Iwaki M; Kinoshita T; Tanino T; Paku T
J Pharm Sci; 1994 Jan; 83(1):34-7. PubMed ID: 8138906
[TBL] [Abstract][Full Text] [Related]
48. Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug.
Otagiri M; Imai T; Fukuhara A
J Control Release; 1999 Nov; 62(1-2):223-9. PubMed ID: 10518654
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach.
Flores-Murrieta FJ; Ko HC; Flores-Acevedo DM; López-Muñoz FJ; Jusko WJ; Sale ME; Castañeda-Hernández G
J Pharmacokinet Biopharm; 1998 Oct; 26(5):547-57. PubMed ID: 10205770
[TBL] [Abstract][Full Text] [Related]
50. Effect of experimental hypoalbuminemia on the plasma protein binding of tolmetin.
Pérez-Urizar J; Flores-Murrieta FJ; Castañeda-Hernández G
Life Sci; 2002 Jul; 71(9):1015-22. PubMed ID: 12088761
[TBL] [Abstract][Full Text] [Related]
51. Blood concentration profiles of acetaminophen following oral administration of fatty acid esters of acetaminophen with pancreatic lipase to dogs.
Bauguess CT; Fincher JH; Sadik F; Hartman CW
J Pharm Sci; 1975 Sep; 64(9):1489-92. PubMed ID: 1185563
[TBL] [Abstract][Full Text] [Related]
52. Prodrug approaches to enhancement of physicochemical properties of drugs IX: acetaminophen prodrug.
Hussain A; Kulkarni P; Perrier D
J Pharm Sci; 1978 Apr; 67(4):545-6. PubMed ID: 25330
[TBL] [Abstract][Full Text] [Related]
53. 4-acetamidophenyl 2,2,2-trichloroethyl carbonate. Particle size studies in animals and man.
Dittert LW; Adams HJ; Alexander F; Chong CW; Ellison T; Swintosky JV
J Pharm Sci; 1968 Jul; 57(7):1146-51. PubMed ID: 5690844
[No Abstract] [Full Text] [Related]
54. Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.
Yáñez JA; Remsberg CM; Sayre CL; Forrest ML; Davies NM
Ther Deliv; 2011 May; 2(5):643-72. PubMed ID: 21837267
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic study of 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole)acetate in the rat.
Sabater J; Domenéch J; Obach R
Arzneimittelforschung; 1993 Feb; 43(2):154-9. PubMed ID: 8457238
[TBL] [Abstract][Full Text] [Related]
56. On the mechanism of the pharmacological activity of the new nonsteroidal antiinflammatory agent 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole)acetate.
Ucelay M; Lasheras B; Cenarruzabeitia E
Arzneimittelforschung; 1989 May; 39(5):586-9. PubMed ID: 2757675
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological study of the new nonsteroidal antiinflammatory agent 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole)acetate.
Ucelay M; Lasheras B; Cenarruzabeitia E
Arzneimittelforschung; 1988 Apr; 38(4):546-51. PubMed ID: 3401269
[TBL] [Abstract][Full Text] [Related]
58. Comparative study of the gastrointestinal tolerability of tolmetin and 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole) acetate (AU-8001).
Rimbau V; Fernández E; Torralba A; Sabater J
Arzneimittelforschung; 1983; 33(6):831-3. PubMed ID: 6604531
[TBL] [Abstract][Full Text] [Related]
59. [Preliminary pharmacological studies of a new anti-inflammatory agent: 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole)acetate].
Cenarruzabeitia E; Lasheras B; Fontan JL
Boll Chim Farm; 1982 Mar; 121(3):97-105. PubMed ID: 6982052
[No Abstract] [Full Text] [Related]
60. Reduction of oral bioavailability of paracetamol by tolmetin in rat.
Sabater J; Peraire C; Obach R; Moreno J; Domenech J
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():61-5. PubMed ID: 1820937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
